DA-JC1

DA-JC1 is a **dual agonist peptide drug** designed to activate both the **glucagon-like peptide 1 receptor** (GLP-1 receptor) and the **glucose-dependent insulinotropic polypeptide receptor** (GIP receptor)[3][5][1]. Its mechanism aims to combine the beneficial effects of GLP-1 and GIP signaling, which includes enhanced hypoglycemic efficacy (improved glucose lowering) and notable **neuroprotective effects** in preclinical models. DA-JC1 has demonstrated protection against oxidative stress, preservation of dopaminergic neurons, reduction of neuroinflammation, enhancement of growth-factor signaling (Akt, CREB, BDNF, GDNF), and activation of cellular autophagy pathways in animal models of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease[3][5][1]. It is notably more effective than GLP-1R agonist monotherapy in both metabolic and neuroprotective contexts[1][3][5].